Phase 3 clinical trial

Also known as: Phase 3 trial, Phase III trial, pivotal trial, registrational trial

A Phase 3 clinical trial is the large, late-stage study designed to confirm that a drug is effective and to characterize its safety in the patient population it is meant to treat. Positive Phase 3 results usually form the core of an NDA or BLA.

How it works

Phase 3 trials typically enroll from several hundred to several thousand patients, often across many sites and countries. Most are randomized, double-blind and controlled against placebo or the current standard of care. The design, including the primary endpoint and statistical analysis plan, is usually agreed with the FDA in advance.

Historically the FDA has often expected two adequate and well-controlled trials, though one large trial plus confirmatory evidence can be enough, particularly for serious or rare diseases. Independent data monitoring committees review unblinded data during the study and can recommend stopping early for overwhelming efficacy, futility or safety.

Trials labeled "pivotal" or "registrational" are the ones intended to support approval, which can include some Phase 2 studies.

Why it matters for traders

Phase 3 readouts are among the most consequential events in biotech. For a company with one late-stage asset, topline data can swing the stock 50% or more either way. Traders weigh:

  • The prior Phase 2 effect and whether Phase 3 was powered realistically.
  • Endpoint choice and FDA alignment.
  • Interim analyses and the risk of early stops.
  • Competition from drugs reading out in the same indication.

Example

Northwind Therapeutics (NWTX) enrolls 900 patients, randomized 2:1 to drug or placebo (600 and 300). The primary endpoint is the share of patients achieving remission at 52 weeks: 36% on drug versus 18% on placebo, an 18-point difference with p < 0.001. NWTX plans its BLA submission within six months.

FAQ

How long do Phase 3 trials take?

Commonly one to four years, depending on enrollment speed and how long patients must be followed to measure the endpoint.

What happens after a successful Phase 3?

The sponsor typically submits an NDA or BLA to the FDA, which sets a PDUFA goal date once the application is accepted.

Track it on Quantisnow

Related terms

Part of the Quantisnow financial glossary. For longer explainers, see the investing guides. Educational content, not investment advice.